Revolution Medicines' RAS(ON) Multi-Selective Inhibitor Daraxonrasib Granted U.S. FDA Orphan Drug Designation in Pancreatic Cancer GlobeNewswire October 27, 2025 REDWOOD CITY, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that the U.S. Food and Drug Administration […]

Elicio Therapeutics Reports Robust T cell Responses Across Diverse HLA backgrounds in Ongoing Phase 2 AMPLIFY-7P Trial GlobeNewswire October 27, 2025 ELI-002 7P demonstrated robust mKRAS-specific T cell responses across a broad range of HLA types, highlighting its potential for use among a diverse patient population Patients treated with ELI-002 7P represented a diverse HLA

Foremost Clean Energy Appoints Seasoned Mining Executive Peter Espig to Board of Directors GlobeNewswire October 27, 2025 VANCOUVER, British Columbia, Oct. 27, 2025 (GLOBE NEWSWIRE) — Foremost Clean Energy Ltd. (NASDAQ: FMST) (CSE: FAT) (“Foremost” or the “Company“), is pleased to announce the appointment of Peter Espig to its Board of Directors, effective immediately. Mr.

AlphaTON (Nasdaq:ATON) and Cyncado Therapeutics: Preclinical Mesothelioma Data Show Direct A2B Tumor Activity; TT-4 Achieved >90% Tumor Growth Inhibition; First-Patient Dosing on Track for Q1 2026 Post-conference recap highlights direct anti-tumor effects in epithelial and non-epithelioid mesothelioma models, >90% tumor growth inhibition in vivo when TT-4 was combined with anti-PD-1, and superior monotherapy activity versus

Greenridge Exploration Receives Airborne MobileMT Survey Results for the Sabre Uranium Project in Athabasca Basin, Saskatchewan GlobeNewswire October 27, 2025 VANCOUVER, British Columbia, Oct. 27, 2025 (GLOBE NEWSWIRE) — Greenridge Exploration Inc. (“Greenridge” or the “Company“) (CSE: GXP | FRA: HW3 | OTCQB: GXPLF), is pleased to announce the results of a high-resolution helicopter-borne Mobile

Harvard-Stanford Study Features Byrna as the Exclusive Product Used to Measure Shift in Gun-Owner Attitudes Toward Non-Lethal Personal Defense Groundbreaking national research finds exposure to Byrna's products significantly increases Americans' openness to non-lethal protection and willingness to support policies promoting safer alternatives GlobeNewswire October 27, 2025 ANDOVER, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) — Byrna

Cocrystal Pharma Receives NIH SBIR Award to Advance its Influenza Inhibitor Program GlobeNewswire October 27, 2025 BOTHELL, Wash., Oct. 27, 2025 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces it has received a Small Business Innovation Research (SBIR) Phase I award from the National Institutes of Health (NIH) National Institute

Maxus Mining Reports on Exploration Insights at the Lotto Project in British Columbia Untapped Tungsten and Critical Mineral Potential in the Trail Creek Mining Division GlobeNewswire October 27, 2025 VANCOUVER, British Columbia, Oct. 27, 2025 (GLOBE NEWSWIRE) — “Maxus” or the “Company”) (CSE: MAXM | FRA: R7V), is pleased to provide a summary of exploration

Spaarne Gasthuis to Advance its Commitment to Patient Care with Proscia's Software Top clinical teaching hospital is laying the foundation for AI-driven disease diagnosis and research GlobeNewswire October 27, 2025 HAARLEM, Netherlands and PHILADELPHIA, Oct. 27, 2025 (GLOBE NEWSWIRE) — Spaarne Gasthuis, a top clinical teaching hospital serving part of the Greater Amsterdam region, is

Franklin Electric Declares Quarterly Dividend of $0.265 per Share GlobeNewswire October 27, 2025 FORT WAYNE, Ind., Oct. 27, 2025 (GLOBE NEWSWIRE) — Franklin Electric Co., Inc. (NASDAQ: FELE) announced today that its Board of Directors declared a quarterly cash dividend of $0.265 per share payable November 20, 2025, to shareholders of record on November 6,